Axogen, Inc. Reports Preliminary Revenue for the First Quarter 2020, Provides Business Update in Response to COVID-19 Pandemic, and Announces Dismissal of Class Action Lawsuit
Axogen, Inc. (AXGN)
Last axogen, inc. earnings: 2/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.axogeninc.com
Company Research
Source: GlobeNewswire
ALACHUA, Fla., April 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary first quarter 2020 revenue, provided a business update on its actions in response to the COVID-19 pandemic, and announced the dismissal of its class-action lawsuit. First quarter 2020 net revenue is estimated to be approximately $24.3 million, an increase of approximately 4% over the first quarter 2019. Although revenue exiting February was trending toward the Company’s annual guidance, hospital reallocation of resources toward the COVID-19 pandemic, along with deferrals and restrictions placed on elective procedures, had a material negative impact on revenue in March. Additionally, management believes that demand for the Company’s products has been temporarily reduced as nationwide shelter-in-place orders have lowered the incidence of traumatic injuries. In response to t
Show less
Read more
Impact Snapshot
Event Time:
AXGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXGN alerts
High impacting Axogen, Inc. news events
Weekly update
A roundup of the hottest topics
AXGN
News
- AxoGen (NASDAQ:AXGN) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
- AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at Lake Street Capital.MarketBeat
- AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
- Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) [Yahoo! Finance]Yahoo! Finance
- Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)GlobeNewswire
AXGN
Earnings
- 10/29/25 - Beat
AXGN
Sec Filings
- 12/4/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 144
- AXGN's page on the SEC website